Cyclacel pharmaceuticals regains compliance with nasdaq minimum bid price requirement

Berkeley heights, n.j., jan. 08, 2024 (globe newswire) -- cyclacel pharmaceuticals, inc. (nasdaq: cycc, nasdaq: cyccp; "cyclacel" or the "company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, announced today that it received a notification letter from the listing qualifications department of the nasdaq stock market ("nasdaq") on january 4, 2024, indicating that the company has regained compliance with the minimum bid price requirement set forth in rule 5550(a)(2) of the nasdaq listing rules.
CYCC Ratings Summary
CYCC Quant Ranking